Today on Stockhouse
Your opinion matters. Submit an article to Stockhouse today at submissions@stockhouse.com. Submission guidelines can be found here.
Dr. George Huang of Growth Stock Wire believes this fall will be crazy for these biotech stocks.
While Nick Thomas of Oxbury Research wonders if oil is going into a boom or bust cycle and how to play it.
Top Bullboards post: Posting to the Yukon Nevada Gold (TSX: T.YNG, Stock Forum) board, aristoenigma noted: “Tons of discussion on this board. Most of it healthy and interesting. There is no question it is a unanimous view by shareholders that YNG is an extremely valuable proposition. Most of us have thought so for the last several years. Now some breakthroughs have occurred and it sounds as if good things will continue to occur. The Nevada operation is about ready to mill gold again at a decent cost. There is a lot of already mined ore ready to be eaten. And there are scads or square miles of rich ore viens owned by YNG that will feed the mill for twenty or thirty plus years (my opinion). Let's see how the week goes with the share price. I see oil is up in Tokyo and Hong Kong and it's midnight here Sunday night. Could be interesting this week. Here's looking forward to the days of $2.00 per share financings again.”
Top Bullboard: Timminco Limited (TSX: T.TIM, Stock Forum)received the most reads and the third-most posts on a day its shares soared 54%.
Top blog: caldernet provided an updated report on legal insider trading for many Canadian-listed companies in the $100,001 Goal blog.
For news about small stocks that made big moves in Monday’s trading, please read the Stockhouse Canadian Small and Micro-cap Stock Report.
Word on Wall Street
"The recovery is moving faster than analysts can sharpen their pencils and revise their estimates upward," said Burt White, chief investment officer at LPL Financial, in an interview with Associated Press.
| Selected expected U.S. earnings releases for Tuesday |
| (Consensus Estimates vs. Last Year) |
|
| Caterpillar (NYSE: CAT) |
Q3 |
$0.06 vs. $1.39 |
|
| DuPont (NYSE: DD) |
Q3 |
$0.33 vs. $0.56 |
|
| First Cash Financial Services (NASDAQ: FCFS) |
Q3 |
$0.34 vs. $0.30 |
|
| Gilead Sciences (NASDAQ: GILD) |
Q3 |
$0.67 vs. $0.59 |
|
| Pfizer( (NYSE: PFE) |
Q3 |
$0.48 vs. $0.62 |
|
| Yahoo! (NASDAQ: YHOO) |
Q3 |
$0.07 vs. $0.09 |
|
| Selected expected Canadian earnings releases for Tuesday |
| (Consensus Estimates vs. Last Year) |
|
| Canadian National Railway (TSX: T.CNR) |
Q3 |
US$0.82 vs. $1.03 |
Today In The Markets
New York markets rise on positive earnings, Toronto stocks lifted by commodities
|
| DJIA |
10,092.19 |
+96.28 |
 |
|
| NASDAQ |
2,176.32 |
+19.52 |
|
|
| S&P500 |
1,097.91 |
+10.23 |
|
|
| S&P/TSX |
11,538.39 |
+33.63 |
|
|
| S&P/TSX Venture |
1,338.77 |
+7.20 |
|
|
New York & Toronto (The Canadian Press) - The Toronto stock market posted a modest gain Monday as further weakness in the U.S. dollar boosted commodity prices.
The S&P/TSX composite index rose 33.63 points to 11,538.39 as the main index also received support from the financial sector. National Bank climbed 88 cents to $59.58.
The Dow Jones industrial average rose 96.28 points to 10,092.19.
The Nasdaq composite index moved 19.52 points higher to 2,176.32 ahead of earnings being released later in the day by Apple Inc. and Texas Instruments Inc., while the S&P 500 index was up 10.23 points to 1,097.91.
Please click here for the complete U.S. and Canadian market summaries.
After-Hours News
Apple (NASDAQ: APPL, Stock Forum)
The company behind the Mac, iPod and iTunes reported fiscal fourth quarter earnings jumped 46% from its year ago quarter. Apple said after the bell on Monday that profits rose to $1.67 billion or $1.82 per share from $1.14 billion or $1.26 per share a year ago. Revenue climbed to $9.87 billion from $7.9 billion a year ago. Analysts were forecasting a profit of $1.42 per share on revenue of $9.2 billion. Looking ahead, the company said it expects to report earnings per share between $1.70 and $1.78 on revenue in a range between $11.3 billion and $11.6 billion.
Angiotech Pharmaceuticals (TSX: T.ANP, Stock Forum)
The company announced after the bell on Monday that it had received correspondence from the FDA regarding its submission for Bio-Seal. The regulatory body declared that Bio-Seal is a class III device that requires Pre-Market Approval. As a result, the company is weighing its options with regard to proceeding to gain FDA marketing approval for the treatment, including appealing the decision. Bio-Seal helps improve the existing technology to diagnose lung cancer by reducing the rates of pneumothorax, a potential medical emergency wherein air or gas is present in the pleural cavity.